Design Therapeutics DSGN Cash Flow Statement (2020-2026)

NASDAQ DSGN
$11.10 +0.46 (+4.32%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Design Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Design Therapeutics reported cash from operations of -$15.52M and free cash flow of -$15.54M for the quarter ended Jun 2026, down 7.5% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-11.32M-11.07M-13.27M-15.00M-17.70M-17.34M-19.29M-19.94M-15.79M-11.84M-11.11M-11.79M-13.04M-13.65M-17.72M-19.08M-17.00M-16.00M-17.64M-20.17M
Depreciation and DepletionDep. & Depletion
0.03M0.08M0.08M0.09M0.11M0.12M0.13M0.13M0.14M0.14M0.14M0.15M0.15M0.15M0.16M0.15M0.16M0.16M0.16M0.15M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.03M0.08M0.08M0.09M0.11M0.12M0.13M0.13M0.14M0.14M0.14M0.15M0.15M0.15M0.16M0.15M0.16M0.16M0.16M0.15M
Share-based CompensationStock Comp.
1.24M1.56M2.36M2.62M2.87M3.08M3.43M3.72M3.22M2.72M3.18M3.30M3.12M3.47M3.54M3.99M3.59M3.44M3.92M3.87M
Other non-cash itemsOther Non-Cash
0.01M0.01M0.02M0.01M0.01M0.01M0.01M0.01M0.01M0.00M0.00M0.00M0.00M0.00M0.00M-0.01M-0.01M0.07M0.07M
Change in Working Capital
Change in Accured ExpensesChange Accured Exp.
1.37M-0.03M0.22M1.60M3.16M0.42M-1.75M3.07M0.24M-2.81M-2.52M-0.72M1.02M1.01M-0.30M0.54M2.41M1.84M-2.51M0.96M
Change in Other Operating AssetsOther Assets Change
-0.47M-0.20M1.24M-0.22M1.90M0.47M-1.19M-0.60M0.64M-0.82M0.41M0.63M-0.66M-0.61M1.41M-0.45M-0.46M0.88M0.29M0.39M
Change in Other Operating LiabilitiesOther Liabilities Change
Other Working Capital ChangesOther WC Changes
0.47M0.20M-1.24M0.22M-1.90M-0.47M1.19M0.60M-0.64M0.82M-0.41M-0.63M0.66M0.61M-1.41M0.45M0.46M-0.88M-0.29M-0.39M
Cash from OperationsCash from Ops.
-8.16M-9.23M-11.83M-10.50M-13.90M-15.09M-17.42M-13.80M-14.53M-12.80M-12.44M-11.26M-9.55M-9.86M-16.79M-14.44M-11.16M-11.97M-16.43M-15.52M
Investing Activities
Capital ExpendituresCapex
0.97M0.35M0.08M0.24M0.31M0.29M0.09M0.09M0.05M0.03M0.20M0.16M-0.02M0.07M0.09M0.03M0.02M
Change in Property, Plant and EquipmentChange in PP&E
-0.97M-0.35M-0.08M-0.24M-0.31M-0.29M-0.09M-0.09M-0.05M-0.03M-0.20M-0.16M0.02M-0.07M-0.09M-0.03M-0.02M
Purchase of InvestmentsInvestments Purchased
4.32M49.91M94.01M61.01M33.62M62.37M54.57M74.15M45.66M53.63M66.51M64.37M86.55M39.53M78.08M87.62M52.59M12.42M
Sale and Maturity of InvestmentsInvestments Sold
0.25M0.20M0.49M1.23M30.94M60.24M53.44M74.44M69.89M79.74M66.47M81.13M60.67M66.21M94.49M59.74M84.59M76.08M45.00M27.50M
Cash from Investing ActivitiesCash from Investing
-5.04M-50.06M0.41M-156.96M-63.39M-1.06M19.73M11.98M15.27M5.56M20.62M27.33M-5.83M1.83M7.87M20.12M6.51M-11.58M-7.59M15.06M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Non-Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
0.03M0.00M0.16M0.15M0.02M0.01M0.40M0.02M0.01M0.00M0.01M0.02M0.04M25.03M19.93M0.14M
Net Shares Issued and RepurchasedNet Shares Issued
0.03M0.00M0.16M0.15M0.02M0.01M0.40M0.02M0.01M0.00M0.01M0.02M0.04M25.03M19.93M0.14M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.03M0.00M0.16M0.15M0.02M0.01M0.40M0.02M0.01M0.00M0.01M0.02M0.04M25.03M19.93M0.14M
Cash from Financing ActivitiesCash from Financing
0.03M0.19M0.16M-0.20M0.15M0.13M0.01M0.50M0.02M0.23M0.00M0.26M0.02M0.36M0.04M25.32M19.93M0.61M
Additional items
Change in Cash
-13.18M-59.09M-11.26M-167.66M-77.14M-16.02M2.31M-1.61M0.75M-6.74M8.20M16.30M-15.37M-7.77M-8.90M6.04M-4.62M1.77M-4.09M0.14M
Ending Cash Balance
357.66M298.57M287.31M119.65M42.52M26.50M28.81M27.20M27.94M21.20M29.40M45.70M30.33M22.56M13.67M19.70M15.09M16.86M12.77M12.91M
Free Cash FlowFCF
-9.13M-9.58M-11.90M-10.74M-14.21M-15.38M-17.51M-13.89M-14.59M-12.83M-12.63M-11.42M-9.53M-9.86M-16.86M-14.53M-11.16M-12.00M-16.43M-15.55M
Net Cash FlowNCF
-13.18M-59.09M-11.26M-167.66M-77.14M-16.02M2.31M-1.82M0.75M-6.74M8.20M16.30M-15.37M-7.77M-8.90M6.04M-4.62M1.77M-4.09M0.14M
Interest Paid

Design Therapeutics Cash Flow Statement API

Pull Design Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=DSGN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY